Features of the management tactics of a patient with menopausal metabolic syndrome

The aim of the study was to study the features of the management tactics of a patient with menopausal metabolic syndrome. We examined the results of the examination and treatment of patient M, 55 years old, diagnosed with grade 1 obesity (BMI 30 kg/m2). Impaired glucose tolerance. Dyslipidemia. Menopausal syndrome. Arterial hypertension 1 st degree. The patient was recommended moderate physical activity, with calorie restriction up to 1400 kcal, and a hypocholesterolemic diet. A drug was prescribed, which is a combination of estradiol 1.0 mg with drosperinone 2.0 mg, HMG-CoA reductase inhibitor 5 mg per day, orlistat with an improved safety profile 120 mg 3 times a day after meals, metformin 1000 mg. The complex treatment was carried out for 6 months with a follow-up examination after 6 months. The patient’s hot flashes stopped, sleep returned to normal, night sweats and headache did not bother her. After 6 months, the weight decreased to the initial body weight. The body mass index after 6 months was 25 kg/m2, which is the norm. The waist circumference after 6 months was 74 cm. Blood pressure stably corresponded to 120/70 mm Hg. Taking antihypertensive drugs was not required. Total cholesterol after 6 months was 4.8 mmol/l. The patient was recommended to continue treatment with subsequent examination annually. Thus, menopausal metabolic syndrome can be considered as one of the variants of the manifestation of menopausal syndrome, which requires an integrated approach to diagnosis and therapy. Individually selected menopausal hormone therapy, being an effective means of relieving the manifestations of menopausal syndrome, also contributes to a positive effect on the components of the metabolic syndrome in this age period. This clinical case demonstrates the need for an individual integrated approach to the management of patients of this age period, with the inclusion of MGT drug, which most effectively has a therapeutic effect due to its pharmacological characteristics.

menopausal metabolic syndrome, menopausal hormone therapy, insulin resistance, dyslipidemia

1. Smetnik V.P. [Medicine menopause]. Moscow. 2006. 847 P. (In Russ.)@@ Медицина климактерия / под ред. В. П. Сметник. Москва, 2006. - C 847.

2. Il’ina L.M., Yureneva S. V., Dubrovina A. V. et al. The influence of menopause on life of working women: the problem without necessary attention.Russian Journal of Human Reproduction. 2016;22(1):87-94. (In Russ.) doi: 10.17116/repro201622187-94.@@ Ильина Л. М., Юренева С. В., Дубровина А. В. и др. Влияние менопаузы на работающих женщин: фактор, которому не придается должного значения. Проблемы репродукции. 2016;22(1):87-94. doi: 10.17116/repro2 01622187-94.

3. Paoletti A. M., Lello S., Di Carlo C. et al. Effect of Estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation. Gynecol Endocrinol. 2016;32(1):61-64. doi: 10.3109/09513590.2015.1079175.

4. Yureneva S. V., Il’ina L.M., Ebzieva Z. Kh. [Fire Flickering in the Vessels: Female Reproductive Aging and Endothelial Dysfunction]. Status Praesens. 2015;6(29):45-52. (In Russ.)@@ Юренева С. В., Ильина Л. М., Эбзиева З. Х. Огонь, мерцающий в сосудах. Репродуктивное старение женщин и эндотелиальная дисфункция. Status Praesens. 2015;6(29):45-52.

5. Mikkola T. S., Savolainen-Peltonen H., Venetkoski M. et al. New evidence for cardiac benefit of postmenopausal hormone therapy. Climacteric. 2017;20(1):5-10. doi: 10.1080/13697137.2016.1262839.

6. Heistad D. D. Unstable coronary-artery plaques. N Engl J Med. 2003;349(24):2285-2287. doi: 10.1056/NEJMp038161.

7. Liu Y., Ding J., Bush T. L. et al. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol. 2001;154(6):489-494. doi: 10.1093/aje/154.6.489.

8. Baber R. J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: 10.3109/13697137.2015.1129166.

9. Griffiths A., MacLennan S.J., Hassard J. Menopause and work: an electronic survey of employees’ attitudes in the UK. Maturitas. 2013;76(2):155-159. doi: 10.1016/j.maturitas.2013.07.005.

10. Yureneva S. V., Ilyina L. M. Female reproductive system aging: From theory to clinical practice. Part 2. Role of hormone therapy in solving the problems of transition stage and early postmenopause. Obstetrics and Gynegology. 2014;4:17-24. (In Russ.)@@ Юренева С. В., Ильина Л. М. Старение репродуктивной системы женщин: от теории к практике. Часть II: Роль гормональной терапии в решении проблем переходного периода и ранней менопаузы. Акушерство и гинекология. 2014;4:17-24.

11. Tankó L. B., Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med. 2005;258(6):544-553. doi: 10.1111/j.1365-2796.2005.01571.x.